Document Detail


Parathyroid hypertensive factor predicts efficacy in the treatment of essential hypertension with verapamil.
MedLine Citation:
PMID:  8860098     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Parathyroid hypertensive factor (PHF) is a circulating hypertensive factor, levels of which are inversely related to renin profile. Given this relationship, it was hypothesized that a PHF level might serve as an alternate predictor of antihypertensive efficacy in hypertensive patients, avoiding the difficulties associated with renin profiling. To test this hypothesis, thirty patients with essential hypertension were placed on 240 mg once daily of a slow release verapamil preparation for a period of one month following a one month run-in period. Results showed an average reduction in mean arterial pressure (MAP)of -7 mmHg (range -5 to - 18) and an average reduction in PHF of -4 mmHg (range 7 to -28). Pre-treatment PHF level correlated with the blood pressure response to verapamil (r = -0.61, p = 0.0004). There was no correlation between any index of renin status and blood pressure. The only other correlation of note was between normalized, ionized calcium and change in blood pressure (r = -0.46, p =0.02). In a forward stepwise multivariate model with MAP as the dependent variable, PHF and normalized, ionized calcium levels were the only biochemical or demographic predictors of response to verapamil. These results suggest that PHF level may be useful in determining the initial choice of antihypertensive agent in hypertensive patients.
Authors:
R Z Lewanczuk; P G Hamilton
Related Documents :
11004688 - Malignant hypertension - the role of the paracrine renin-angiotensin system.
9740618 - Association between a polymorphism in the g protein beta3 subunit gene and lower renin ...
842668 - Dissociation of renal blood flow and filtration rate autoregulation by renin depletion.
4292638 - Nature of the pressor substance in rabbit placenta.
7049708 - Ticrynafen and hydrochlorothiazide. a comparison in hypertensive patients with renal im...
18256578 - State of hypertension management in the united states: confluence of risk factors and t...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Blood pressure     Volume:  5     ISSN:  0803-7051     ISO Abbreviation:  Blood Press.     Publication Date:  1996 Mar 
Date Detail:
Created Date:  1997-05-29     Completed Date:  1997-05-29     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9301454     Medline TA:  Blood Press     Country:  NORWAY    
Other Details:
Languages:  eng     Pagination:  98-104     Citation Subset:  IM    
Affiliation:
Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antihypertensive Agents / therapeutic use*
Biological Factors / blood*
Drug Administration Schedule
Female
Humans
Hypertension / blood,  drug therapy*
Male
Middle Aged
Prognosis
Renin / blood*
Statistics, Nonparametric
Treatment Outcome
Verapamil / therapeutic use*
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Biological Factors; 0/parathyroid hypertensive factor; 52-53-9/Verapamil; EC 3.4.23.15/Renin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Adverse effects on risk of ischaemic heart disease of adding sugar to hot beverages in hypertensives...
Next Document:  Low dose of ACE-inhibitor enhances sodium excretion in volume expanded patients with borderline hype...